Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.
OncLive’s April Roundup of Key FDA Decisions in Oncology
Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma
The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma
FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
NXC-201 Receives Orphan Drug Designation in the European Union for Multiple Myeloma
Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer
Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer